Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A

Next Previous
Trial Profile

A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PATHFINDER 2
  • Sponsors Novo Nordisk

Most Recent Events

  • 01 Jan 2022 Results of post-hoc analysis of two studies (pathfinder 2 and pathfinder 5) assessing long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis, published in the Haemophilia.
  • 01 Jan 2022 Post hoc analysis was performed by applying datamining techniques retrospectively to the final results of the pathfinder 2 and 3 clinical trials and analysing the resulting data descriptively; results published in the Haemophilia
  • 19 Nov 2020 A pharmacodynamic pharmacokinetic decision model was developed to predict comparative bleed outcomes of adults and adolescents with severe haemophilia A receiving treatment with EHL FVIIIs, capturing differences in cumulative bleeding episodes and breakthrough bleed resolution and resource costs; results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top